These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

The shocking rise in health complications linked to weight-loss drugs like Ozempic has ignited a fierce debate about the efficacy and safety of these medications. Originally designed as diabetes ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

Feb. 21, the Food and Drug Administration said there is no longer a short supply of the weight loss and diabetes drugs Wegovy ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

High-end brands are churning through creative directors as they try to revive sales.

UnitedHealth shares fall after WSJ flags Justice Department investigation. Follow along for live updates on stocks and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.